KRAS-Mutant MSS Metastatic Colorectal Cancer (2L)
ONCYOncolytics BiotechCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Pelareorep + Bevacizumab + FOLFIRI (Oncolytic Virus) in KRAS-Mutant MSS Metastatic Colorectal Cancer (2L). The expected timing is based on the latest available company guidance and may change.
02/04/26:- Received Fast Track Designation. Study starts March 2026; interim data Q4 2026. 03/02/26:- REO 033 Ph2 study initiated; first site March 2026. Preliminary data expected Q4 2026. 05/04/26:- REO 022 showed 19.5-month median DOR; FDA engagement ongoing for accelerated approval path. 07/13/26:- Sites activate Jul-Aug 2026. Type D FDA meeting Aug 2026; Part A response update YE 2026; Part B Q1 2027. 08/18/26:- FDA written feedback aligns on potential pivotal REO 033 Part B; End-of-Phase meeting planned; Type D canceled.
Verification
Confirm timing and program details against the company announcement or filing.